论文部分内容阅读
目的分析微生态制剂对缓解缺血性肠炎患者临床症状和减少并发症的效果。方法纳入108例缺血性肠炎患者分为观察组(56例)和对照组(52例),对照组采用常规治疗,观察组在常规治疗基础上加用微生态制剂,比较两组患者血浆D-二聚体水平、症状缓解时间、并发症发生率及治疗效果。结果治疗后两组患者D-二聚体水平均下降(P<0.01),且观察组下降较对照组明显(F=124.65,P<0.01)。对照组腹痛、腹泻和便血的缓解时间分别为(4.20±0.58)、(2.81±0.48)和(5.13±0.53)d,均长于观察组的(2.78±0.48)、(1.71±0.47)和(3.28±0.49)d(P<0.01)。对照组并发症发生率为21.15%,高于观察组的7.14%(P<0.05);对照组治愈率为23.08%,低于观察组的42.86%(P<0.05)。结论常规治疗联合微生态制剂可有效改善缺血性肠炎患者临床症状,治疗效果优于单纯常规治疗。
Objective To analyze the effect of probiotics on relieving clinical symptoms and reducing complications in patients with ischemic enteritis. Methods One hundred and eighty patients with ischemic enteritis were divided into observation group (56 cases) and control group (52 cases). The control group was treated with conventional therapy. The observation group was treated with probiotics on the basis of routine treatment. The plasma D - dimer level, symptom relief time, complication rate and therapeutic effect. Results After treatment, the levels of D-dimer decreased in both groups (P <0.01), and the decrease in observation group was more obvious than that in control group (F = 124.65, P <0.01). (4.20 ± 0.58), (2.81 ± 0.48) and (5.13 ± 0.53) d in the control group were longer than those in the observation group (2.78 ± 0.48, 1.71 ± 0.47 and 3.28 ± 0.49) d (P <0.01). The incidence of complications in the control group was 21.15%, which was 7.14% (P <0.05) in the observation group. The cure rate in the control group was 23.08%, which was lower than 42.86% in the observation group (P <0.05). Conclusion Conventional treatment combined with probiotics can effectively improve the clinical symptoms of patients with ischemic enteritis, the treatment effect is better than the simple routine treatment.